What is Eurofins DiscoverX?
Eurofins DiscoverX is a prominent provider of advanced cell-based assays and services, primarily catering to the pharmaceutical and biotechnology industries. The company specializes in developing innovative solutions for drug discovery and development, including assays for characterizing agonistic antibodies, screening kinase inhibitors, and advancing therapeutics for critical conditions such as cancer, autoimmune diseases, obesity, and diabetes. Their comprehensive suite of products and custom capabilities aims to expedite the drug development pipeline for their clients.
How much funding has Eurofins DiscoverX raised?
Eurofins DiscoverX has raised a total of $13.4M across 2 funding rounds:
Private Equity
$5.4M
Private Equity
$8M
Private Equity (2008): $5.4M, investors not publicly disclosed
Private Equity (2010): $8M, investors not publicly disclosed
What's next for Eurofins DiscoverX?
The substantial enterprise-level funding and recent strategic investment position Eurofins DiscoverX for significant expansion and innovation. This capital is likely to be deployed towards enhancing their assay development platforms, broadening their service portfolio, and potentially exploring new therapeutic areas. The company's focus on providing reliable and advanced solutions suggests a strategic direction aimed at solidifying its market leadership and supporting the evolving needs of drug discovery research.
See full Eurofins DiscoverX company page
